Provided by Tiger Trade Technology Pte. Ltd.

Glaukos

165.69
+4.402.73%
Post-market: 165.690.00000.00%19:30 EDT
Volume:1.20M
Turnover:196.42M
Market Cap:9.77B
PE:-51.05
High:166.97
Open:160.06
Low:159.89
Close:161.29
52wk High:191.62
52wk Low:73.16
Shares:58.98M
Float Shares:56.44M
Volume Ratio:0.90
T/O Rate:2.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2456
EPS(LYR):-3.2819
ROE:-25.98%
ROA:-5.18%
PB:14.32
PE(LYR):-50.49

Loading ...

Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint

TIPRANKS
·
Oct 09

Glaukos Says Phase 4 Trial Shows iDose TR Plus Cataract Surgery Cuts Mean Diurnal IOP More than Surgery Alone

Reuters
·
Oct 09

Glaukos Corporation - Phase 4 Study Meets Primary Efficacy Endpoint with Statistically Significant Iop Reduction

THOMSON REUTERS
·
Oct 09

Glaukos Corporation - Idose Tr Demonstrates Favorable Safety Profile Through 3 Months

THOMSON REUTERS
·
Oct 09

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating Idose® Tr in Combination with Cataract Surgery

THOMSON REUTERS
·
Oct 09

Glaukos falls -7.4%

TIPRANKS
·
Oct 08

Glaukos announces exclusive license agreement with RevOpsis for RO-104

TIPRANKS
·
Oct 08

Glaukos Signs Exclusive License Deal with RevOpsis for Retinal Biologic RO-104

Reuters
·
Oct 08

Glaukos Corporation - Financial Terms of Agreement not Disclosed

THOMSON REUTERS
·
Oct 08

Glaukos Announces Exclusive License Agreement with Revopsis Therapeutics to Develop and Commercialize Ro-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

THOMSON REUTERS
·
Oct 08

Glaukos Stock Has The Bull Case Changed After Higher 2026 Sales Guidance

Simply Wall St.
·
Oct 08

Glaukos Chief Development Officer Tomas Navratil Disposes of $251,194 in Common Shares

Reuters
·
Oct 08

Glaukos Says Late-Stage Eye Disease Treatment Shows Lasting Benefits After Single Dose

Reuters
·
Oct 08

Glaukos Says Phase 3 Extension Study Shows Epioxa Epi-on Corneal Cross-Linking Benefits Durable Through Three Years in Keratoconus

Reuters
·
Oct 08

Glaukos Corporation - no Serious Adverse Events or Discontinuations Reported in Three Years After Epioxa

THOMSON REUTERS
·
Oct 08

Glaukos Corporation - Three-Year Follow-up Shows Durable Efficacy and Favorable Safety for Epioxa

THOMSON REUTERS
·
Oct 08

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

THOMSON REUTERS
·
Oct 08

Movement Alert|Glaukos Rises 6.57% in Regular Trading, 2026 Sales Guidance Materially Raised

Market Focus
·
Oct 07

Glaukos Schedules Third-Quarter 2026 Results Release, Conference Call

Reuters
·
Oct 07

What Glaukos Holders Were Betting On All Along

Simply Wall St.
·
Oct 07